Calidi Biotherapeutics Shares Plunge 35.04% After Public Offering Announcement

Written by Emily J. Thompson, Senior Investment Analyst

Source: Benzinga

Updated: 19 hours ago

0mins

CLDI-53.14%

Should l Buy CLDI?

Source: Benzinga

Public Offering Announcement: Calidi Biotherapeutics has announced an underwritten public offering, planning to issue units of common stock or pre-funded warrants, with an expected 45-day overallotment option for underwriters to purchase up to 15% additional shares, which may dilute existing shareholders' stakes further.
Significant Stock Drop: Following the announcement, Calidi's shares plummeted 35.04% in after-hours trading to $0.50, reflecting a strong negative market reaction to the financing plan, and the stock has fallen 92.45% over the past 12 months, indicating severe loss of market confidence.
Market Performance Analysis: With a Relative Strength Index (RSI) of 38.68, Calidi's stock is in an oversold condition, currently holding a market capitalization of $5.55 million and trading close to its 52-week low of $0.72, highlighting investor concerns regarding its future outlook.
Use of Proceeds: The company stated that the proceeds from the offering will be used for working capital and general corporate purposes; however, the market's lack of confidence in its financial health may impact its future financing capabilities and business development.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy CLDI?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on CLDI

About CLDI

Calidi Biotherapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is developing proprietary allogeneic stem cell-based and enveloped virus platforms to potentiate and deliver oncolytic viruses (vaccinia virus and adenovirus) and, potentially, other molecules to cancer patients. It is focused on developing two proprietary stem cell-based platforms and one enveloped vaccinia virus platform designed to protect the oncolytic virus, whether natural or engineered, from neutralization by the patient’s immune defenses, allowing for greater infection of the tumor cells and leading to a potential improvement in the antitumor activity of oncolytic viruses over traditional naked oncolytic virus therapies. Its product candidates include the CLD-101 product for high grade glioma (HGG), CLD-101 product for Recurrent HGG, CLD-201 product for solid tumors, CLD-301 (AAA) for multiple indications and CLD-400 (RTNova) for certain lung cancer and metastatic solid tumors.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

U.S. Stocks Decline Amid Weak Retail Sales Data

8 hours agoBenzinga

Market Performance: U.S. stocks broadly declined during trading, with the S&P 500 falling approximately 1%, the Dow down 0.99% to 47,479.25, and the NASDAQ dropping 0.86% to 22,554.26, indicating market concerns over economic outlook.
Retail Sales Data: U.S. retail sales fell by 0.2% month-over-month in January, missing market estimates of a 0.3% decline, reflecting weak consumer spending that could negatively impact economic growth.
Sector Movements: While the overall market declined, energy stocks rose by 0.5%, contrasting with a 2.1% drop in financial stocks, indicating sector divergence that may influence investor asset allocation strategies.
International Market Dynamics: European shares fell broadly, with the eurozone's STOXX 600 down 1.04%, while Asian markets mostly gained, suggesting varying performances across regions that could affect global investor confidence.

Calidi Biotherapeutics Prices Public Offering of 10.52M Units

12 hours agoseekingalpha

Offering Size: Calidi Biotherapeutics announced the pricing of 10.52 million units at $0.50 each, expecting to raise approximately $5.2 million in gross proceeds for working capital and general corporate purposes after underwriting discounts and expenses.
Underwriting Arrangement: Ladenburg Thalmann & Co. Inc. is acting as the sole book-running manager for the offering, granting underwriters a 45-day option to purchase up to 1.575 million additional shares and warrants, enhancing market liquidity.
Warrant Terms: Each unit consists of one share of common stock and three warrants exercisable over six months, twelve months, and five years, aimed at attracting investors and enhancing shareholder value.
Existing Warrant Amendment: The company agreed to amend existing warrants to reduce the exercise price to $0.50 per share upon the offering's closing, further boosting investor confidence and optimizing capital structure.

U.S. Stocks Decline as Unemployment Rate Rises

12 hours agoBenzinga

Market Weakness: U.S. stocks traded lower this morning, with the Nasdaq Composite falling over 300 points and the S&P 500 dropping 1.38% to 6,736.10, reflecting investor concerns over economic data that may impact market confidence.
Nonfarm Payrolls Decline: The Bureau of Labor Statistics reported a loss of 92,000 nonfarm payrolls in February 2026, significantly below economists' expectations of 59,000, indicating signs of economic slowdown that could lead to further market volatility.
Unemployment Rate Increase: The unemployment rate unexpectedly ticked up to 4.4%, surpassing forecasts of 4.3%, which may raise concerns about economic recovery and affect consumer spending and business investment.
Energy Stocks Resilience: Despite the overall market decline, energy shares rose by 1%, indicating that certain sectors are showing resilience in an uncertain economic environment, potentially attracting investor interest.

Calidi Biotherapeutics Prices Public Offering of 10.5 Million Units

13 hours agoNewsfilter

Offering Size: Calidi Biotherapeutics announced the pricing of its public offering of 10,519,631 units at $0.50 per unit, with expected gross proceeds of approximately $5.2 million, reflecting the company's proactive financing strategy in the capital markets.
Warrant Structure: Each unit consists of one share of common stock and three different warrants with varying terms of 6 months, 12 months, and 5 years, designed to attract investors and enhance liquidity, thereby increasing shareholder value.
Over-Allotment Option: The underwriter has a 45-day option to purchase up to an additional 1,575,000 shares, which further boosts market confidence in Calidi and provides flexibility for future financing.
Use of Proceeds: The net proceeds from the offering will be used for working capital and general corporate purposes, indicating the company's strategic decision to advance its gene therapy research and market expansion efforts.